Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders
Bambusa Therapeutics has raised approximately $90 million in an oversubscribed Series A financing round14.
The funding round was led by new investor RA Capital Management, with participation from Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management14.
Bambusa's lead candidate, BBT001, is a bispecific antibody targeting dermatological conditions and is currently in phase 1 testing1.
The company has developed BBT002, a bispecific antibody with potential applications in respiratory, dermatology, and gastroenterology indications14.
Bambusa was founded in May 2024 and previously raised $15 million in seed funding in September 202425.
The new funds will support the advancement of Bambusa's lead programs through Phase I clinical trials and drive further pipeline development14.
Dr. Derek DiRocco, Partner at RA Capital Management, will join Bambusa's Board of Directors4.
Bambusa's bispecific antibodies are designed to target complementary disease-driving signaling pathways, aiming for a best-in-disease profile for patients14.
The company is led by CEO and Founder Shanshan Xu, M.D., Ph.D., who previously held leadership roles at BioNTech and Berenberg Capital Markets1.
Bambusa is based in Boston and focuses on developing transformative inflammatory and immunological therapeutics5.
Sources:
1. https://www.fiercebiotech.com/biotech/boston-biotech-bambusa-banks-90m-next-gen-bispecifics
2. https://pulse2.com/bambusa-therapeutics-15-million-seed-raised-to-develop-bispecific-antibodies/
4. https://www.prnewswire.com/news-releases/bambusa-therapeutics-raises-approximately-90-million-in-series-a-financing-to-advance-next-generation-bispecific-antibodies-for-immunology--inflammation-diseases-302376866.html
5. https://www.prnewswire.com/news-releases/bambusa-therapeutics-inc-announces-successful-series-seed-funding-to-advance-innovative-bispecific-antibodies-for-immunology--inflammation-302241958.html